Adjuvant Whole Breast Irradiation in Five Fractions Versus Fifteen Fractions in Early Breast Cancer
NCT ID: NCT05112341
Last Updated: 2021-11-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
50 participants
OBSERVATIONAL
2021-06-01
2023-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
group 1 standared hypofractonation
radiation therapy
the patient first is simulated then delineation is done
group 2 fast forward group
radiation therapy
the patient first is simulated then delineation is done
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
radiation therapy
the patient first is simulated then delineation is done
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* breast conservation surgery
* Stages (pT1-3, pN0-1, M0) breast cancer.
* Any histological type of invasive breast cancer.
* All grades of breast cancer (I,II,III)
Exclusion Criteria
* Metastatic breast cancer (MBC)
* Recurrent breast cancer.
* Patients' co-morbidities that contraindicate radiotherapy
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sohag University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Heba Ali Elsagheer
assistant lecturer of oncolgy. sohag university hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sohag University Hospital
Sohag, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
mohamed s gaber, professor
Role: CONTACT
Phone: 01025876769
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Osama R ElSherif, professor
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H. Cancer incidence in egypt: results of the national population-based cancer registry program. J Cancer Epidemiol. 2014;2014:437971. doi: 10.1155/2014/437971. Epub 2014 Sep 21.
Mascaro A, Farina M, Gigli R, Vitelli CE, Fortunato L. Recent advances in the surgical care of breast cancer patients. World J Surg Oncol. 2010 Jan 20;8:5. doi: 10.1186/1477-7819-8-5.
Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thurlimann B, Senn HJ; Panel Members. Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015 Aug;26(8):1533-46. doi: 10.1093/annonc/mdv221. Epub 2015 May 4.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
soh-Med-21-10-17
Identifier Type: -
Identifier Source: org_study_id